Aquestive Therapeutics, Inc. AQST Business Segments — Total Costs & Expenses

Similar metrics at other companies

SVCOReportable Segment — Total Costs & Expenses

$23.62M-29.2%

PCRXReportable Segment — Total Costs & Expenses

$170.47M+2.1%

SDReportable Segment — Total Costs & Expenses

$31.92M+5.0%

GRALReportable Segment — Total Costs & Expenses

$176.55M-4.8%

GRNDReportable Segment — Total Costs & Expenses

$87.21M+27.2%

TARSReportable Segment — Total Costs & Expenses

$168.18M+60.8%

Questions, answered.

What is Aquestive Therapeutics, Inc.'s business segments — total costs & expenses?

Aquestive Therapeutics, Inc. (AQST) reported business segments — total costs & expenses of $18.65M in Q1 2026.

How has Aquestive Therapeutics, Inc.'s business segments — total costs & expenses changed year-over-year?

Aquestive Therapeutics, Inc.'s business segments — total costs & expenses decreased by 33.6% year-over-year, from $28.09M to $18.65M.

What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — total costs & expenses?

Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — total costs & expenses has grown at a 32.7% compound annual growth rate (CAGR), from $65.69M to $115.6M.

What does business segments — total costs & expenses mean?

The total sum of all operating costs, including manufacturing, research, development, and administrative overhead incurred by the segment. This metric provides a holistic view of the total resource consumption required to sustain the segment's current operations and pipeline development. It is used to evaluate the overall cost structure and profitability profile of the business unit.